February 21, 2006: Novartis and Alnylam announce new collaboration to develop RNAi therapeutics for pandemic flu
November 7, 2005: Mark Fishman elected member of the Institute of Medicine
October 3, 2005: Novartis named top employer in Science survey
September 20, 2005: Novartis presents positive Phase III data on key compounds and highlights strong late-stage development pipeline
September 7, 2005: Media release: Novartis and Alnylam create major alliance to discover RNAi therapeutics
August 29, 2005: Mark Fishman - the President of the Novartis Institutes for BioMedical Research - was awarded the 2005 Pharmaceutical Achievement Award for Chief Scientific Officer of the Year.
Visit the Pharmaceutical Achievement Awards website
August 1, 2005: Jeremy Levin, Global Head of Strategic Alliances, awarded the Albert Einstein Award for Outstanding Achievement in the Life Sciences
July 15: Novel mechanism to interrupt transport of protein to cell surface, a Nature publication by NIBR scientists
May 21, 2005: Media release: FTY720 shows promising results in the treatment of multiple sclerosis
May 18, 2005: NIBR Headquarters building in Cambridge named Lab of the Year
May 11, 2005: NIBR Science Spring 2005 issue is out
May 3, 2005: Novartis Preclinical Research Day for investors in Cambridge
April 19, 2005: An expanding role for DPP4 in the control of beta cell function
April 4, 2005: Findings from FMI and NIBR scientists may improve cancer treatment
March 21, 2005: Novartis Institutes participates in public-private consortium to accelerate basic research
March 18, 2005: Beta-site specific intrabodies to decrease and prevent generation of Alzheimer's A-beta peptide, a paper published in Journal of Cell Biology by NIBR Basel scientists.
Read a review of the article
February 24, 2005: What's wrong with our cancer models? A review by Alexander Kamb, the Head of the Oncology disease area, in Nature Reviews in Drug Discovery.
Read a summary of the article
February 14, 2005: NIBR chemists' work recognized as a "Chemistry Highlight 2004"
January 21, 2005: As part of the Financial Results 2004 Conference, Mark Fishman – the President of the Novartis Institutes for BioMedical Research – led the workshop "Change the grammar of drug discovery". In another workshop entitled “Insights Into Drug Discovery,” scientific leaders from research and development described recent Novartis scientific advances.
January 20, 2005: At a Research & Development review presented at its Financial Results 2004 Conference, Novartis provided an update on its industry-leading pipeline, announcing robust progress in 75 development projects, including 43 new molecular entities, that aim to address unmet medical needs.
January 5, 2005: Novartis and Infinity announce small molecule collaboration
